Literature DB >> 26265223

Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.

Peter B Bach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26265223      PMCID： PMC4571809          DOI： 10.1634/theoncologist.2015-0257

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  Pem and the cost of multicycle maintenance.

Authors:  Peter A Learn; Peter B Bach
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

2.  Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?

Authors:  Daniel A Goldstein; Bassel F El-Rayes
Journal:  Oncologist       Date:  2015-08-11

3.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

4.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

5.  Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Authors:  Sham Mailankody; Vinay Prasad
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

6.  Indication-specific pricing for cancer drugs.

Authors:  Peter B Bach
Journal:  JAMA       Date:  2014 Oct 22-29       Impact factor: 56.272

7.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113
  7 in total
  2 in total

1.  Low-value practices in oncology contributing to financial toxicity.

Authors:  Bishal Gyawali
Journal:  Ecancermedicalscience       Date:  2017-03-16

Review 2.  Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.

Authors:  Alex Françoso; Patricia Ucelli Simioni
Journal:  Drug Des Devel Ther       Date:  2017-01-11       Impact factor: 4.162
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.